Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers

[1]  S. Bens,et al.  Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma. , 2017, Cancer research.

[2]  M. Mazaheri,et al.  Association of XRCC2 rs3218536 Polymorphism with Susceptibility of Breast and Ovarian Cancer: A Systematic Review and Meta-Analysis , 2017, Asian Pacific journal of cancer prevention : APJCP.

[3]  Gayle Patel,et al.  A study of over 35,000 women with breast cancer tested with a 25‐gene panel of hereditary cancer genes , 2017, Cancer.

[4]  P. Devilee,et al.  Functional Analysis of Missense Variants in the Putative Breast Cancer Susceptibility Gene XRCC2 , 2016, Human mutation.

[5]  T. Walsh,et al.  Inherited Mutations in Women With Ovarian Carcinoma. , 2016, JAMA oncology.

[6]  S. Cross,et al.  No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing , 2016, Journal of Medical Genetics.

[7]  Y. Drew.  The development of PARP inhibitors in ovarian cancer: from bench to bedside , 2015, British Journal of Cancer.

[8]  M. Akbari,et al.  Genetic testing for RAD51C mutations: in the clinic and community , 2015, Clinical genetics.

[9]  Lara E Sucheston-Campbell,et al.  Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Jiang,et al.  Arg188His polymorphism in the XRCC2 gene and the risk of ovarian cancer: a meta-analysis. , 2015, Genetics and molecular research : GMR.

[11]  J. Surrallés,et al.  Fanconi anemia: a model disease for studies on human genetics and advanced therapeutics. , 2015, Current opinion in genetics & development.

[12]  M. Jasin,et al.  Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. , 2015, Cold Spring Harbor perspectives in biology.

[13]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[14]  F. Nielsen,et al.  Identification of a breast cancer family double heterozygote for RAD51C and BRCA2 gene mutations , 2015, Familial Cancer.

[15]  H. Nevanlinna,et al.  RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families , 2015, SpringerPlus.

[16]  R. Schwab,et al.  Breast cancer in a RAD51D mutation carrier: case report and review of the literature. , 2015, Clinical breast cancer.

[17]  Nazneen Rahman,et al.  Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.

[18]  Á. Carracedo,et al.  RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families , 2014, Breast Cancer Research and Treatment.

[19]  H. Gevensleben,et al.  Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers , 2014, Virchows Archiv.

[20]  B. Kong,et al.  Analyzing Association of the XRCC3 Gene Polymorphism with Ovarian Cancer Risk , 2014, BioMed research international.

[21]  J. Benítez,et al.  About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants , 2014, International journal of cancer.

[22]  Jane E. Carpenter,et al.  Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. , 2014, Carcinogenesis.

[23]  Yazhou He,et al.  Impact of XRCC2 Arg188His Polymorphism on Cancer Susceptibility: A Meta-Analysis , 2014, PloS one.

[24]  T. Frebourg,et al.  Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes , 2014, European Journal of Human Genetics.

[25]  A. Meindl,et al.  RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families , 2013, Breast Cancer Research.

[26]  A. Nicolas,et al.  Germline mutation in the RAD51B gene confers predisposition to breast cancer , 2013, BMC Cancer.

[27]  R. Eeles,et al.  Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. , 2013, Journal of the National Cancer Institute.

[28]  Wei Zheng,et al.  Evaluating Genome-Wide Association Study-Identified Breast Cancer Risk Variants in African-American Women , 2013, PloS one.

[29]  R. Rouzier,et al.  Germline RAD51C mutations in ovarian cancer susceptibility , 2013, Clinical genetics.

[30]  Y. Bang,et al.  RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib , 2013, Molecular Cancer Therapeutics.

[31]  S. Powell,et al.  Rad51 Paralog Complexes BCDX2 and CX3 Act at Different Stages in the BRCA1-BRCA2-Dependent Homologous Recombination Pathway , 2012, Molecular and Cellular Biology.

[32]  F. Couch,et al.  Rare variants in XRCC2 as breast cancer susceptibility alleles , 2012, Journal of Medical Genetics.

[33]  A. Ashworth,et al.  Genome-wide association study identifies a novel variant in RAD51B associated with male breast cancer risk , 2012, Nature Genetics.

[34]  Jean-Philippe Vert,et al.  Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants , 2012, Human mutation.

[35]  S. Seal,et al.  Germline RAD51C mutations confer susceptibility to ovarian cancer , 2012, Nature Genetics.

[36]  Daniel J. Park,et al.  Rare mutations in XRCC2 increase the risk of breast cancer. , 2012, American journal of human genetics.

[37]  J. Benítez,et al.  Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families. , 2012, Human molecular genetics.

[38]  W. Foulkes,et al.  Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families , 2012, British Journal of Cancer.

[39]  Samantha E. Boyle,et al.  Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients , 2012, Hereditary Cancer in Clinical Practice.

[40]  Wu Wei,et al.  Association between the XRCC3 polymorphisms and breast cancer risk: meta-analysis based on case–control studies , 2011, Molecular Biology Reports.

[41]  Michael Jones,et al.  Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. , 2011, Human molecular genetics.

[42]  Jane E. Carpenter,et al.  Common breast cancer susceptibility loci are associated with triple-negative breast cancer. , 2011, Cancer research.

[43]  Deborah Hughes,et al.  Germline mutations in RAD51D confer susceptibility to ovarian cancer , 2011, Nature Genetics.

[44]  A. Mannermaa,et al.  Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility , 2011, Breast Cancer Research and Treatment.

[45]  Dieter Niederacher,et al.  Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene , 2010, Nature Genetics.

[46]  W. Willett,et al.  A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1) , 2009, Nature Genetics.

[47]  A. Zharkikh,et al.  Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral , 2005, Journal of Medical Genetics.

[48]  J. Klijn,et al.  Pathology of Ovarian Cancers in BRCA1 and BRCA2 Carriers , 2004, Clinical Cancer Research.

[49]  N Risch,et al.  Genetic analysis of breast cancer in the cancer and steroid hormone study. , 1991, American journal of human genetics.